Halozyme Signs GSK Deal for Subcutaneous ADC Delivery, First Trial in 2026
HALO•Halozyme entered a global collaboration and license agreement with GSK to use its ENHANZE® technology for subcutaneous formulations of multiple oncology targets, including antibody drug conjugates, with first clinical trial expected in 2026. The deal includes an upfront payment, potential milestone payments and royalties, expanding Halozyme’s high-margin royalty revenue business.
1. Deal Terms
Halozyme entered a global collaboration and license agreement with GSK to develop subcutaneous formulations of multiple oncology targets, including antibody drug conjugates, and secure an option for additional future targets under its ENHANZE® technology.
2. Financial Structure
GSK will make an upfront payment to Halozyme and is responsible for potential development and sales-based milestone payments, while Halozyme will earn royalties on net sales of any products incorporating ENHANZE®. The first clinical trial is projected to initiate in 2026.
3. Strategic Impact
This agreement marks Halozyme’s first collaboration on subcutaneous delivery of ADCs, expanding its addressable market and reinforcing the durability of its high-margin royalty revenue model by leveraging ENHANZE® across a rapidly growing therapeutic class.
